A reduced dose of elective radiation is safe and does not compromise treatment efficacy in patients with head and neck ...

Adding perioperative pembrolizumab to standard care can improve EFS in locally advanced head and neck cancer, data suggest.

Adding pembrolizumab (Keytruda), before and after surgery, to standard adjuvant therapy for locally advanced head and neck ...

Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in ...

Reducing the dose of radiation to nodal regions is safe and does not impact the risk of recurrence in patients with head and neck cancer, a study suggests.

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

The FDA is currently reviewing Merck’s sBLA for Keytruda in head and neck cancer, with a target action date of June 23.

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck ...

In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 ...

locally advanced head and neck squamous cell carcinoma (HNSCC), according to data from the first interim analysis of KEYNOTE-689. These data support changing the current standard of care in these ...